Abstract 100P
Background
Colon cancer (CC) is one of the most common malignancies in the world. In this study, we investigated the involvement of a mitosis related chromosome condensation protein NCAPG in tumor progression, and in the prognosis of human CC.
Methods
The patient cohort in this study consisted of 123 CC cases from 2009 to 2013, documenting pathologic and clinical factors, as well as clinical outcomes. Immunohistochemistry and immunoblotting were employed to examine the NCAPG expression in 123 pairs of normal and CC tissues and 7 colon cells. Based on the expression of NCAPG, one CC cell with high NCAPG level was chosen for knockdown of NCAPG expression. The effect of NCAPG knockdown on the growth, migration and invasion of NCAPG-manipulated CC cells was examined.
Results
NCAPG protein overexpression was observed in 88 patients and was significantly correlated with depth of invasion, distant metastasis, staging, and poor disease-free and overall survival. Multivariate Cox regression analysis showed that NCAPG overexpression is an indenpendent prognostic marker for CC. Furthermore, NCAPG expression was elevated in several CC cells. In vitro experiments indicated that NCAPG knockdown inhibited CC cell growth, migration and invasion.
Conclusions
This study suggests that overexpression of NCAPG can be a useful marker for predicting the outcome of CC patients and that NCAPG targeting can represent a potential modality for treating CC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Chi Mei Medical Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract